Intravenous Zotatifin in Adults With Mild or Moderate COVID-19 (PROPEL)
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial of Intravenous Zotatifin in Adults With Mild or Moderate Coronavirus Disease 2019 (COVID-19)
Sponsor: Effector Therapeutics
This PHASE1 trial investigates Corona Virus Infection and is currently completed. Effector Therapeutics leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
-
Mar 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
May 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — May 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Effector Therapeutics
- Medpace, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .